Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 7/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 7/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 5/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392243 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRM5SIGMAR1ESR1 | |
| SCHEMBL3394459 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRM5SIGMAR1ESR1 | |
| SCHEMBL18587456 | 0.84 | GRIN2B (0.74) | GRIN1GRIN2BDRD2DRD1DRD4 | |
| SCHEMBL3396820 | 0.84 | GRIN2B (0.74) | GRIN1GRIN2BDRD2DRD1DRD4 | |
| SCHEMBL3394777 | 0.84 | GRIN2B (0.74) | GRIN1GRIN2BDRD2DRD1DRD4 | |
| SCHEMBL3394780 | 0.84 | GRIN2B (0.74) | GRIN1GRIN2BDRD2DRD1DRD4 | |
| SCHEMBL3390701 | 0.82 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL3772950 | 0.82 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL3395790 | 0.82 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL3390698 | 0.82 | GRIN1 (1.00) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | WESTFALISCHE WILHELMS-UNIVERSITAT MUNSTER (DE) | 2018-09-06 | — | — | US | disclosed |
| EP-2246331-A1 | NR2B-selective NMDA-receptor antagonists | Westfälische Wilhelms-Universität Münster (DE) | 2010-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | GRIN1, GRIN2B, GRIN3B | GRIN1 1/4885GRIN2B 2/4885GRM5 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.